Consolidated Statements of Income - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Aug. 31, 2024 |
Aug. 31, 2023 |
Aug. 31, 2024 |
Aug. 31, 2023 |
|
| Revenue | $ 8,066,715 | $ 7,869,875 | $ 23,961,761 | $ 23,466,980 |
| Costs and Expenses: | ||||
| Cost of sales | 2,125,846 | 2,156,187 | 6,311,064 | 6,366,737 |
| Selling, general and administrative expenses | 4,149,785 | 3,804,564 | 12,510,787 | 11,722,435 |
| Change in fair value of contingent consideration | 12,702 | 122,671 | 3,829 | (65,154) |
| Research, development and related engineering | 193,933 | 344,132 | 937,907 | 727,648 |
| Depreciation and amortization | 194,559 | 281,277 | 287,543 | 843,201 |
| Total costs and expenses | 6,676,825 | 6,708,831 | 20,359,130 | 19,594,867 |
| Operating Income | 1,389,890 | 1,161,044 | 3,602,631 | 3,872,113 |
| Other Income (Expense): | ||||
| Gains on marketable securities | 522,458 | 93,386 | 1,056,052 | 100,082 |
| Gain on interest rate swap | 0 | 282,731 | 105,887 | 58,757 |
| Other income | 981 | 102 | 1,181 | 3,436 |
| Interest expense | (533,464) | (469,642) | (1,119,196) | (1,405,825) |
| Total other income (expense) | (10,025) | (93,423) | 43,924 | (1,243,550) |
| Income before income tax expense | 1,379,865 | 1,067,621 | 3,646,555 | 2,628,563 |
| Income tax expense | (328,186) | (387,060) | (1,382,845) | (960,214) |
| Net income | $ 1,051,679 | $ 680,561 | $ 2,263,710 | $ 1,668,349 |
| Net income per common share - basic | $ 0.13 | $ 0.08 | $ 0.28 | $ 0.2 |
| Weighted average common shares outstanding - basic | 8,061,946 | 8,286,555 | 8,151,967 | 8,358,792 |
| Net income per common share - diluted | $ 0.13 | $ 0.08 | $ 0.27 | $ 0.2 |
| Weighted average common shares outstanding - diluted | 8,173,535 | 8,342,067 | 8,241,488 | 8,374,939 |
| Tianhe Stem Cell Biotechnologies Inc [Member] | ||||
| Costs and Expenses: | ||||
| Impairment of investment | $ 0 | $ 0 | $ 308,000 | $ 0 |
| Processing and Storage Fees [Member] | ||||
| Revenue | 7,945,470 | 7,862,949 | 23,716,492 | 23,006,164 |
| Public Banking [Member] | ||||
| Revenue | 120,609 | 4,383 | 205,799 | 398,896 |
| Product [Member] | ||||
| Revenue | $ 636 | $ 2,543 | $ 39,470 | $ 61,920 |
| X | ||||||||||
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of realized and unrealized gain (loss) on investment. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment in marketable security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|